Cargando…
Polypharmacy in African American Adults: A National Epidemiological Study
Background: Despite the association between polypharmacy and undesired health outcomes being well established, very little is known about epidemiology of polypharmacy in the African American community. We are not aware of any nationally representative studies that have described the socioeconomic, b...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6630878/ https://www.ncbi.nlm.nih.gov/pubmed/30934828 http://dx.doi.org/10.3390/pharmacy7020033 |
_version_ | 1783435399073366016 |
---|---|
author | Assari, Shervin Helmi, Hamid Bazargan, Mohsen |
author_facet | Assari, Shervin Helmi, Hamid Bazargan, Mohsen |
author_sort | Assari, Shervin |
collection | PubMed |
description | Background: Despite the association between polypharmacy and undesired health outcomes being well established, very little is known about epidemiology of polypharmacy in the African American community. We are not aware of any nationally representative studies that have described the socioeconomic, behavioral, and health determinants of polypharmacy among African Americans. Aims: We aimed to investigate the socioeconomic and health correlates of polypharmacy in a national sample of African American adults in the US. Methods: The National Survey of American Life (NSAL, 2003–2004) included 3,570 African American adults. Gender, age, socioeconomic status (SES; education attainment, poverty index, and marital status), access to the healthcare system (health insurance and having a usual source of care), and health (self-rated health [SRH], chronic medical disease, and psychiatric disorders) in addition to polypharmacy (5 + medications) as well as hyper-polypharmacy (10 + medications) were measured. Logistic regressions were applied for statistical analysis. Results: that About 9% and 1% of all African American adults had polypharmacy and hyper-polypharmacy, respectively. Overall, higher age, higher SES (education and poverty index), and worse health (poor SRH, more chronic medical disease, and psychiatric disorders) were associated with polypharmacy and hyper-polypharmacy. Individuals with insurance and those with a routine place for healthcare also had higher odds of polypharmacy and hyper-polypharmacy. Conclusions: Given the health risks associated with polypharmacy, there is a need for systemic evaluation of medication use in older African Americans with multiple chronic conditions. Such policies may prevent medication errors and harmful drug interactions, however, they require effective strategies that are tailored to African Americans. |
format | Online Article Text |
id | pubmed-6630878 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-66308782019-08-19 Polypharmacy in African American Adults: A National Epidemiological Study Assari, Shervin Helmi, Hamid Bazargan, Mohsen Pharmacy (Basel) Article Background: Despite the association between polypharmacy and undesired health outcomes being well established, very little is known about epidemiology of polypharmacy in the African American community. We are not aware of any nationally representative studies that have described the socioeconomic, behavioral, and health determinants of polypharmacy among African Americans. Aims: We aimed to investigate the socioeconomic and health correlates of polypharmacy in a national sample of African American adults in the US. Methods: The National Survey of American Life (NSAL, 2003–2004) included 3,570 African American adults. Gender, age, socioeconomic status (SES; education attainment, poverty index, and marital status), access to the healthcare system (health insurance and having a usual source of care), and health (self-rated health [SRH], chronic medical disease, and psychiatric disorders) in addition to polypharmacy (5 + medications) as well as hyper-polypharmacy (10 + medications) were measured. Logistic regressions were applied for statistical analysis. Results: that About 9% and 1% of all African American adults had polypharmacy and hyper-polypharmacy, respectively. Overall, higher age, higher SES (education and poverty index), and worse health (poor SRH, more chronic medical disease, and psychiatric disorders) were associated with polypharmacy and hyper-polypharmacy. Individuals with insurance and those with a routine place for healthcare also had higher odds of polypharmacy and hyper-polypharmacy. Conclusions: Given the health risks associated with polypharmacy, there is a need for systemic evaluation of medication use in older African Americans with multiple chronic conditions. Such policies may prevent medication errors and harmful drug interactions, however, they require effective strategies that are tailored to African Americans. MDPI 2019-03-29 /pmc/articles/PMC6630878/ /pubmed/30934828 http://dx.doi.org/10.3390/pharmacy7020033 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Assari, Shervin Helmi, Hamid Bazargan, Mohsen Polypharmacy in African American Adults: A National Epidemiological Study |
title | Polypharmacy in African American Adults: A National Epidemiological Study |
title_full | Polypharmacy in African American Adults: A National Epidemiological Study |
title_fullStr | Polypharmacy in African American Adults: A National Epidemiological Study |
title_full_unstemmed | Polypharmacy in African American Adults: A National Epidemiological Study |
title_short | Polypharmacy in African American Adults: A National Epidemiological Study |
title_sort | polypharmacy in african american adults: a national epidemiological study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6630878/ https://www.ncbi.nlm.nih.gov/pubmed/30934828 http://dx.doi.org/10.3390/pharmacy7020033 |
work_keys_str_mv | AT assarishervin polypharmacyinafricanamericanadultsanationalepidemiologicalstudy AT helmihamid polypharmacyinafricanamericanadultsanationalepidemiologicalstudy AT bazarganmohsen polypharmacyinafricanamericanadultsanationalepidemiologicalstudy |